-
Start Preamble
By Notice dated March 19, 2007, and published in the Federal Register on March 27, 2007, (72 FR 14297), Roche Diagnostics Operations, Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:
Drug Schedule Lysergic Acid Diethylamide (7315) I Tetrahydrocannabinols (7370) I Alphamethadol (9605) I Phencyclidine (7471) II Ecgonine (9180) II Methadone (9250) II Morphine (9300) II The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products.
No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Roche Diagnostics Operations, Inc., to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Roche Diagnostics Operations, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.
Start SignatureDated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E7-12951 Filed 7-2-07; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 07/03/2007
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- E7-12951
- Pages:
- 36483-36483 (1 pages)
- PDF File:
- e7-12951.pdf